NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free PHVS Stock Alerts $22.60 -0.93 (-3.95%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$22.48▼$23.9050-Day Range$18.42▼$26.4752-Week Range$7.93▼$33.00Volume55,488 shsAverage Volume89,385 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$32.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Pharvaris alerts: Email Address Pharvaris MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside43.8% Upside$32.50 Price TargetShort InterestHealthy0.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 stars 3.3 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePharvaris has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.87% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently increased by 813.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.20) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Pharvaris Stock (NASDAQ:PHVS)Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesApril 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsMay 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.May 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 10, 2024 | investorplace.comPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023April 10, 2024 | globenewswire.comPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 10, 2024 | globenewswire.comPharvaris Appoints David Nassif, J.D., as Chief Financial OfficerApril 4, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceMarch 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97February 22, 2024 | finance.yahoo.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 22, 2024 | globenewswire.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 16, 2024 | finance.yahoo.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 16, 2024 | globenewswire.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 14, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)January 26, 2024 | finance.yahoo.comPharvaris to Present at the WSAAI Annual Meeting 2024January 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory AdvancesJanuary 23, 2024 | finance.yahoo.comPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE ProgramJanuary 22, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksSee More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/10/2024Today5/05/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$32.50 High Stock Price Target$50.00 Low Stock Price Target$11.00 Potential Upside/Downside+43.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.92% Return on Assets-44.45% Debt Debt-to-Equity RatioN/A Current Ratio27.25 Quick Ratio27.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.57Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-3.02 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 65)M.B.A., Co-Founder, CEO & Executive Director Comp: $565.02kMs. Anna Nijdam M.Sc. (Age 43)R.A., Head of Strategic Finance & Principal Accounting Officer Key CompetitorsContext TherapeuticsNASDAQ:CNTXLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPProcaps GroupNASDAQ:PROCView All CompetitorsInstitutional OwnershipBlackstone Inc.Bought 100,000 shares on 2/15/2024Ownership: 0.314%venBio Partners LLCBought 654,832 shares on 2/14/2024Ownership: 15.451%Commodore Capital LPBought 800,000 shares on 2/14/2024Ownership: 2.513%Bain Capital Life Sciences Investors LLCSold 880,355 shares on 2/13/2024Ownership: 0.000%Vivo Capital LLCBought 285,000 shares on 2/7/2024Ownership: 0.000%View All Institutional Transactions PHVS Stock Analysis - Frequently Asked Questions Should I buy or sell Pharvaris stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks. What is Pharvaris' stock price target for 2024? 4 brokers have issued 1-year price objectives for Pharvaris' stock. Their PHVS share price targets range from $11.00 to $50.00. On average, they anticipate the company's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts. How have PHVS shares performed in 2024? Pharvaris' stock was trading at $28.05 on January 1st, 2024. Since then, PHVS shares have decreased by 19.4% and is now trading at $22.60. View the best growth stocks for 2024 here. Are investors shorting Pharvaris? Pharvaris saw a increase in short interest in April. As of April 15th, there was short interest totaling 90,400 shares, an increase of 813.1% from the March 31st total of 9,900 shares. Based on an average daily volume of 102,500 shares, the short-interest ratio is presently 0.9 days. Currently, 0.9% of the shares of the stock are sold short. View Pharvaris' Short Interest. When is Pharvaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PHVS earnings forecast. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) issued its quarterly earnings data on Wednesday, April, 10th. The company reported ($0.80) earnings per share for the quarter. When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHVS) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.